By Daniella Parra Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) said it showed additional safety and tolerability data, marking the second positive Phase 3 study assessing TNX-102 SL for fibromyalgia management. Tonix said the study met its primary endpoint, demonstrating statistically...

By Karen E. Roman Vaxxinity, Inc. (NASDAQ: VAXX) said it will collaborate with the University of Central Florida in the advancement of space medicine research through a grant funded by the state of Florida. The goal is to further develop...

  By Healthcare Edge Editorial Staff DecisionRx, Inc., a value-based healthcare company focused on minimizing healthcare costs by addressing medication failure, announced a $100 million credit facility from global investment firm Carlyle. Carlyle also obtained an option to acquire 25%...

By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA) said it appointed Sanjeev Luther as incoming President and Chief Executive Officer from Jan. 1, 2024. Mr. Luther emphasized his commitment to advancing the reach and promise of mRNA cell...

By Healthcare Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), a pioneer in non-CPAP Obstructive Sleep Apnea (OSA) therapy, has revealed that its precision oral appliance therapy (OAT) devices effectively treat OSA, according to a study published by the Cureus Journal...

By Thomas S. Green Apollomics Inc. (Nasdaq: APLM) said it saw strong results from two clinical trials for Vebreltinib, designed to target non-small cell lung cancer and other advanced tumors. The trials showed that patients without co-occurring MET amplification had...

By Healthcare Edge Editorial Staff Octave Bioscience, Inc. said Founder William Hagstrom will become Chairman of the Board, while Doug Biehn is the new President and CEO. Mr. Biehn has over 20 years of experience in healthcare, building and scaling...

    By Healthcare Edge Editorial Staff SAB Biotherapeutics, Inc. (Nasdaq: SABS), which is trying to slow down the progression of type 1 diabetes, said it started trials of SAB-142 on humans in Australia. SAB-142 is the first fully-human anti-thymocyte...

Healthcare Edge and Exec Edge are please to provide complete video coverage of the third annual Palm Beach CorpGov Forum, which was held on Nov. 8, featuring a full day of panels and fireside chats. The event was composed of over...

By Karen E. Roman Alladapt Immunotherapeutics, Inc., a biopharmaceutical company developing treatment for Immunoglobulin E-mediated food allergy, said it received fast track designation by the U.S. Food and Drug Administration for ADP101, its multi-food oral immunotherapy. ADP101 is designed to...